These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19275632)

  • 1. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I.
    Agadjanyan MG; Cribbs DH
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):1-6. PubMed ID: 19275632
    [No Abstract]   [Full Text] [Related]  

  • 2. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models.
    Busche MA; Grienberger C; Keskin AD; Song B; Neumann U; Staufenbiel M; Förstl H; Konnerth A
    Nat Neurosci; 2015 Dec; 18(12):1725-7. PubMed ID: 26551546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Alzheimer's disease: the beginning of a new era.
    Schenk D
    Curr Alzheimer Res; 2006 Jul; 3(3):177. PubMed ID: 16842091
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse models reveal why Alzheimer's treatment fails.
    Niemeyer JE
    Lab Anim (NY); 2016 Apr; 45(4):125. PubMed ID: 27003340
    [No Abstract]   [Full Text] [Related]  

  • 6. Amyloid-beta immunotherapy for Alzheimer's disease.
    Fu HJ; Liu B; Frost JL; Lemere CA
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
    Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
    Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.
    Cribbs DH; Agadjanyan MG
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):82-7. PubMed ID: 19355929
    [No Abstract]   [Full Text] [Related]  

  • 9. Amyloid-beta immunotherapy: the hope for Alzheimer disease?
    Barrera-Ocampo A; Lopera F
    Colomb Med (Cali); 2016 Dec; 47(4):203-212. PubMed ID: 28293044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Alzheimer disease.
    Gouras GK
    MAbs; 2009; 1(2):112-4. PubMed ID: 20061820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer disease. Could anti-amyloid-β immunotherapy do more harm than good?
    Wood H
    Nat Rev Neurol; 2016 Jan; 12(1):2. PubMed ID: 26610710
    [No Abstract]   [Full Text] [Related]  

  • 12. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current trend of immunotherapy for Alzheimer's disease].
    Matsumoto SE; Tabira T
    Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aβ immunotherapy for Alzheimer's disease].
    Sakai K; Yamada M
    Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative and mechanistic studies of Abeta immunotherapy.
    Golde TE; Das P; Levites Y
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):31-49. PubMed ID: 19275635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antibodies for immunotherapy of Alzheimer's disease].
    Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
    Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
    Schenk DB; Seubert P; Grundman M; Black R
    Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain.
    Morgan D
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):7-15. PubMed ID: 19275633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.